Action Eli Lilly - LLY

Votre Hub pour des idées et discussions en direct en temps réel

Premium

Dernier

30,51

Prix Achat

30,50

Prix Vente

30,55

Volume échangé

19 128

30,50 Fourchette du Jour 30,76

0,00 Plage de 52 semaines 0,00

Clôture Veille

30,66

Ouverture

30,64

Dernière Transaction

100

30.51

Dernière heure de transaction

17:56:21

Volume moyen (3 m)

Volume financier

VWAP

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Form 4 - Statement of changes in beneficial ownership of securities

Lilly confirms date and conference call for fourth-quarter 2024 financial results and 2025 financial guidance announcement

Lilly confirms date and conference call for fourth-quarter 2024 financial results and 2025 financial guidance announcement PR Newswire INDIANAPOLIS, Jan. 23, 2025 INDIANAPOLIS, Jan. 23, 2025...

FDA approves Lilly's Omvoh® (mirikizumab-mrkz) for Crohn's disease, expanding its use to the second major type of inflammatory bowel disease

FDA approves Lilly's Omvoh® (mirikizumab-mrkz) for Crohn's disease, expanding its use to the second major type of inflammatory bowel disease PR Newswire INDIANAPOLIS, Jan. 15, 2025 In the pivotal...

Form 8-K - Current report

Lilly provides update on 2024 revenue guidance, announces 2025 revenue guidance

Lilly provides update on 2024 revenue guidance, announces 2025 revenue guidance PR Newswire INDIANAPOLIS, Jan. 14, 2025 2024 revenue is expected to be approximately $45.0 billion for the full...

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0	0	0	0	0	0	0	DR
4	0	0	0	0	0	0	0	DR
12	0	0	0	0	0	0	0	DR
26	0	0	0	0	0	0	0	DR
52	0	0	0	0	0	0	0	DR
156	0	0	0	0	0	0	0	DR
260	0	0	0	0	0	0	0	DR

LLY - Frequently Asked Questions (FAQ)

What is the current Eli Lilly share price?

The current share price of Eli Lilly is $ 30,51

What is the 1 year trading range for Eli Lilly share price?

Eli Lilly has traded in the range of $ 0,00 to $ 0,00 during the past year

Volume
% Gagnants
% Perdants

Symbole	Prix	Vol.
FHFilament Health Corp	$ 0,03 (20,00%)	160k
CBSTCannabist Company Holdings Inc	$ 0,09 (12,50%)	213,98k
JETGlobal Crossing Airlines Group Inc	$ 0,99 (10,00%)	28,55k
BTQBTQ Technologies Corp	$ 4,80 (2,35%)	164,07k
NOWSServicenow CDR	$ 27,36 (2,17%)	12,09k
CDMNCanadian Manganese Company Inc	$ 0,025 (-16,67%)	244,64k
LITSLithos Energy Ltd	$ 0,03 (-14,29%)	277k
HOLDImmutable Holdings Inc	$ 0,155 (-13,89%)	30,17k
GLAS.A.UGlass House Brands Inc	US$ 5,84 (-4,73%)	23,81k
ALGOLight AI Inc	1,13 (-3,42%)	307,07k
ALGOLight AI Inc	1,13 (-3,42%)	307,07k
LITSLithos Energy Ltd	$ 0,03 (-14,29%)	277k
DEFIValour Inc	$ 4,65 (0,87%)	270,82k
CDMNCanadian Manganese Company Inc	$ 0,025 (-16,67%)	244,64k
CBSTCannabist Company Holdings Inc	$ 0,09 (12,50%)	213,98k

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Eli Lilly and Company (LLY)

Votre Hub pour des idées et discussions en direct en temps réel

Statistiques et détails clés

LLY Dernières nouvelles

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Lilly confirms date and conference call for fourth-quarter 2024 financial results and 2025 financial guidance announcement

FDA approves Lilly's Omvoh® (mirikizumab-mrkz) for Crohn's disease, expanding its use to the second major type of inflammatory bowel disease

Form 8-K - Current report

Lilly provides update on 2024 revenue guidance, announces 2025 revenue guidance

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Lilly confirms date and conference call for fourth-quarter 2024 financial results and 2025 financial guidance announcement

FDA approves Lilly's Omvoh® (mirikizumab-mrkz) for Crohn's disease, expanding its use to the second major type of inflammatory bowel disease

LLY - Frequently Asked Questions (FAQ)

Moteurs

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0	0	0	0	0	0	0	DR
4	0	0	0	0	0	0	0	DR
12	0	0	0	0	0	0	0	DR
26	0	0	0	0	0	0	0	DR
52	0	0	0	0	0	0	0	DR
156	0	0	0	0	0	0	0	DR
260	0	0	0	0	0	0	0	DR

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0	0	0	0	0	0	0	DR
4	0	0	0	0	0	0	0	DR
12	0	0	0	0	0	0	0	DR
26	0	0	0	0	0	0	0	DR
52	0	0	0	0	0	0	0	DR
156	0	0	0	0	0	0	0	DR
260	0	0	0	0	0	0	0	DR

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Eli Lilly and Company (LLY) Cours

Eli Lilly and Company (LLY)

Votre Hub pour des idées et discussions en direct en temps réel

Statistiques et détails clés

LLY Dernières nouvelles

LLY - Frequently Asked Questions (FAQ)

Moteurs

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Supprimer les publicités

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0	0	0	0	0	0	0	DR
4	0	0	0	0	0	0	0	DR
12	0	0	0	0	0	0	0	DR
26	0	0	0	0	0	0	0	DR
52	0	0	0	0	0	0	0	DR
156	0	0	0	0	0	0	0	DR
260	0	0	0	0	0	0	0	DR